See more : Molekule Group, Inc. (MKUL) Income Statement Analysis – Financial Results
Complete financial analysis of PepGen Inc. (PEPG) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of PepGen Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- KOSAIDO Holdings Co., Ltd. (7868.T) Income Statement Analysis – Financial Results
- Diamond Lake Minerals, Inc. (DLMI) Income Statement Analysis – Financial Results
- Bayview Acquisition Corp Unit (BAYAU) Income Statement Analysis – Financial Results
- Tips Films Limited (TIPSFILMS.BO) Income Statement Analysis – Financial Results
- Crypto 1 Acquisition Corp (DAOO) Income Statement Analysis – Financial Results
PepGen Inc. (PEPG)
About PepGen Inc.
PepGen Inc., a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. The company's lead product candidate is PGN-EDO51, an EDO peptide in Phase I clinical trials to treat individuals with Duchenne muscular dystrophy (DMD). It is also developing PGN-EDODM1, an EDO peptide-conjugated PMO for the treatment of myotonic dystrophy type 1, as well as EDO therapeutic candidates, such as PGN-EDO53, PGN-EDO45, and PGN-EDO44 for the treatment of DMD. The company was founded in 2018 and is headquartered in Cambridge, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 1.18M | 493.00K | 178.00K | 110.00K | 106.00K |
| Gross Profit | -1.18M | -493.00K | -178.00K | -110.00K | -106.00K |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 66.94M | 54.08M | 19.00M | 1.02M | 620.00K |
| General & Administrative | 16.64M | 14.22M | 8.11M | 853.00K | 628.00K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 627.37K |
| SG&A | 16.64M | 14.22M | 8.11M | 853.00K | 628.00K |
| Other Expenses | 0.00 | 110.00K | -172.00K | -20.00K | 0.00 |
| Operating Expenses | 84.77M | 68.30M | 27.11M | 1.88M | 1.25M |
| Cost & Expenses | 84.77M | 68.30M | 27.11M | 1.88M | 1.35M |
| Interest Income | 6.40M | 2.79M | 0.00 | 8.00K | 6.00K |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 1.18M | 493.00K | 178.00K | 110.00K | 106.00K |
| EBITDA | -83.58M | -67.81M | -26.93M | -1.77M | -1.25M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -84.77M | -68.30M | -27.11M | -1.88M | -1.35M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 6.21M | 2.90M | -172.00K | -12.00K | 8.00K |
| Income Before Tax | -78.55M | -65.40M | -27.28M | -1.89M | -1.35M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 73.00K | 3.71M | -58.56K | -8.00K | 0.00 |
| Net Income | -78.63M | -69.10M | -27.28M | -1.88M | -1.35M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -3.30 | -2.91 | -1.22 | -0.08 | -0.06 |
| EPS Diluted | -3.30 | -2.91 | -1.22 | -0.08 | -0.06 |
| Weighted Avg Shares Out | 23.80M | 23.71M | 22.39M | 22.39M | 22.39M |
| Weighted Avg Shares Out (Dil) | 23.80M | 23.71M | 22.39M | 22.39M | 22.39M |
PepGen Announces Positive Data from Low-Dose Cohort of PGN-EDO51 in Ongoing CONNECT1-EDO51 Phase 2 Clinical Trial for Treatment of Duchenne Muscular Dystrophy
BOSTON--(BUSINESS WIRE)--PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced positive clinical data from the first dose cohort (5...
Recent Price Trend in PepGen (PEPG) is Your Friend, Here's Why
If you are looking for stocks that are well positioned to maintain their recent uptrend, PepGen (PEPG) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
PepGen Announces Executive Team Promotions
BOSTON--(BUSINESS WIRE)--This is an appointment release for PepGen. They are announcing 2 promotions on their team.
PepGen Reports First Quarter 2024 Financial Results and Recent Corporate Highlights
– CONNECT1-EDO51 trial preliminary data from 5mg/kg dose cohort expected mid-2024 – – FREEDOM1-DM1 trial preliminary data from at least 5mg/kg dose cohort expected second half 2024 – – N et proceeds of $86.3 million from common stock offerings extending...
Best Momentum Stocks to Buy for April 25th
TXO, PEPG and ERO made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on April 25, 2024.
New Strong Buy Stocks for April 25th
TAK, TXO, PEPG, ERO and RMNI have been added to the Zacks Rank #1 (Strong Buy) List on April 25, 2024.
PepGen to Participate in Upcoming Investor Conferences
BOSTON, March 13, 2024 (GLOBE NEWSWIRE) -- PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced that management will...
PepGen Receives U.S. FDA Orphan Drug and Rare Pediatric Disease Designations for PGN-EDO51 for the Treatment of Duchenne Muscular Dystrophy
BOSTON, March 13, 2024 (GLOBE NEWSWIRE) -- PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced that the U.S....
Can PepGen, Inc. (PEPG) Climb 48.62% to Reach the Level Wall Street Analysts Expect?
The mean of analysts' price targets for PepGen, Inc. (PEPG) points to a 48.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside...
PepGen, Inc. (PEPG) Upgraded to Buy: What Does It Mean for the Stock?
PepGen, Inc. (PEPG) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Source: https://incomestatements.info
Category: Stock Reports